Revvity
Revvity, formerly known as PerkinElmer Informatics, is a leading provider of innovative software solutions headquartered in the United States. Established in 2022, the company has quickly positioned itself at the forefront of the life sciences and healthcare industries, focusing on data analytics, laboratory informatics, and scientific data management. With a commitment to enhancing research and development processes, Revvity offers a suite of core products that streamline workflows and improve data accessibility. Their unique approach combines advanced analytics with user-friendly interfaces, enabling organisations to make informed decisions swiftly. Recognised for its significant contributions to the field, Revvity continues to expand its operational reach, serving clients across North America and beyond. The company’s dedication to innovation and excellence has solidified its reputation as a trusted partner in the scientific community.
DitchCarbon Score
How does Revvity's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Revvity's score of 38 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Revvity's reported carbon emissions
In 2023, Revvity reported total greenhouse gas emissions of approximately 29,810,000 kg CO2e, comprising 2,121,000 kg CO2e from Scope 1 and about 27,689,000 kg CO2e from Scope 2 emissions. This represents a slight decrease from 2022, where total emissions were approximately 32,093,000 kg CO2e, with Scope 1 emissions at 2,289,000 kg CO2e and Scope 2 emissions at about 30,370,000 kg CO2e. Revvity has set ambitious climate commitments, aiming for a 50% reduction in Scope 1 and 2 emissions by 2033, starting from their 2022 levels. Additionally, the company is committed to achieving net carbon neutrality by 2040, reflecting a long-term strategy to mitigate their environmental impact. These initiatives align with industry standards for climate action and demonstrate Revvity's dedication to sustainability within the pharmaceuticals and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 2,289,000 | 0,000,000 |
| Scope 2 | 29,844,000 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Revvity is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
